Summary

Targeted therapy largely remains an unmet therapeutic need for low-grade serous ovarian carcinomas. However, recent advances in molecular characterization are beginning to change the landscape. A recent article highlights the association of genetic alterations with clinical outcomes, widening the scope of novel targeted therapies.

See related article by Manning-Geist et al., p. xxx

This content is only available via PDF.
You do not currently have access to this content.